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Background and Significance: Alzheimer’s Disease (AD) is a chronic, 
progressive neurodegenerative disease whose pathogenesis centers 
around the abnormal processing of amyloid precursor protein (APP) by 
proteases, resulting in the formation of neuritic plaques composed of 
toxic, insoluble fragments of amyloid protein (Aβ), including Aβ1-40 and 
Aβ1-42. Previously, our laboratory identified Chlamydia pneumoniae 
(Cpn) in autopsied sporadic AD brains. Additionally, an infection-based 
animal model was developed using BALB/c mice that were intranasally 
inoculated with Cpn, in which the deposition of amyloid was consistent 
with that observed in the human AD brain. These studies have led to the 
pathogen hypothesis of AD that implicates Cpn as a trigger for the 
cleavage of APP into Aβ1-40 and Aβ1-42. 
Objective: Several studies have demonstrated the presence of astrocytes 
surrounding neuritic plaques within the AD brain; therefore, we speculate 
that astrocytes may be specifically involved in the pathological processes 
leading to Aβ deposition. This investigation addresses if an in vitro Cpn 
infection of human astrocytes affects processing of the β amyloid 
precursor protein (βAPP) and the enzyme β-APP cleaving enzyme-1 
(BACE1), a type 1 transmembrane aspartyl protease implicated in 
numerous neurodegenerative diseases.  
Methods: Human astrocytes (CCF-STTG1) were infected in vitro with the 
respiratory strain AR39 Cpn (MOI=1). Analysis of protein levels for Aβ and 
the enzyme BACE1 post-infection was detected by immunocytochemistry 
and captured with the Olympus Confocal FV1000 microscope.  
Results: Amyloid processing in infected astrocytes was altered relative to 
that of uninfected astrocytes. BACE1 immunolabeling appeared more 
diffuse in the uninfected astrocytes as compared to membrane-localized 
BACE1 in the infected astrocytes. 
Conclusions: Neurons have been presumed to be the primary source of 
beta-amyloid peptides in AD brains; however, when astrocytes are 
activated, as occurs during infection with Cpn, astrocytic beta-amyloid 
generation may contribute to amyloid plaque formation. These data 
imply that infection of human astrocytes with Cpn affects the processing 
of βAPP through altering the levels of the BACE1 protease. These data 
suggest an activation of BACE1 in the processing of amyloid by astrocytes 
as a major contributor to the neurotoxic amyloid deposition linked to 
pathology observed in AD.  
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Human Astrocytes Infected with Chlamydia pneumoniae (CPn) and  
Immunolabeled with Antibodies Specific for Isoforms of Aβ and BACE1  
Anti-Beta Amyloid 1-16 (6E10)    
6hr  
48hr 
72hr 
Anti-BACE1 (ab10716)   
+Cpn 
Human astrocytoma cells, CCF-STTG1 (ATCC, CRL1718), were infected with Chlamydia pneumonia 
(CPn, ATCC, 53592) at an MOI of 1 for 6 to 72 hours. The cells were grown on 12mm glass coverslips 
(Neuvitro, GG-12) and stained using CPn direct tag antibodies: 60C19 FITC-direct tag (Fitzgerald, 
5861188) or 61C75A FITC-direct tag (Fitzgerald, 5861504) at a dilution of 1:100. Coverslips were 
washed and labeled with primary amyloid antibodies: 6E10 detecting amino acids 1-16 of Aβ 
(BioLegend, sig-39320) or anti-BACE1 detecting amino acids 485-501 of BACE1 (Abcam, ab10716) at a 
dilution of 1:500. Secondary goat-derived antibodies tagged with Alexa-Fluor 594 (Life Technologies, 
A-11005) were applied after additional washing and blocking steps. The labeled cells were mounted 
on glass slides using FLUORO-GEL II with DAPI (EMS, 17985-50). Samples were observed using a 
Olympus Confocal FV1000 microscope.  
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• The present study investigates the downstream products of βAPP processing in 
human astrocytoma cells infected with a respiratory strain of Chlamydia 
pneumoniae (CPn). Infected astrocytes showed a minimal increase in amyloid 
labeling from 6 hours to 72 hours post infection as compared to that of 
uninfected astrocytes, indicating enhanced βAPP processing at these timepoints.   
• BACE1 labeling was also more robust along the astrocytic membrane after 6 
hours of infection and progressed through 72 hours post infection. 
• The mechanism by which βAPP processing and BACE1 protein levels increase in 
response to cellular stress (e.g. infection) remains to be elucidated. 
Quantification of intracellular and secreted amyloid and enzymatically active 
BACE1 protease would validate these findings. Additionally, mRNA expression 
assays would provide further insight into how both APP and secretase genes are 
regulated in response to an infectious process. 
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Figure 1: Human CCF-STTG1 astrocytes immunolabeled with anti-Chlamydial, anti-amyloid, and anti-BACE1 antibodies. CPn was labeled using FITC direct tag anti-Chlamydia 
antibodies 60C19 and 61C75A. Amino acids 1-16 of Aβ was labeled with 6E10 (mouse, monoclonal) while amino acids 485-501 of BACE1 was labeled with ab10716 (rabbit, 
polyclonal). Secondary antibodies were Alexa-Fluor 594-tagged.  
Processing of Amyloid Precursor Protein 
Background 
Alzheimer’s Disease (AD) is a chronic, progressive neurodegenerative 
disease that afflicts nearly 5.2 million Americans and ranks among the top 10 
causes of death in the US that can neither be prevented nor cured (8). The 
pathogenesis of AD centers on the abnormal proteolytic processing of 
amyloid precursor protein (APP) by proteases such as β-APP cleaving enzyme 
1 (BACE1), resulting in the formation of toxic and insoluble fragments of 
amyloid protein (Aβ) of variable lengths, including Aβ1-40 and Aβ1-42 (6,7) 
that are primarily localized to the hippocampus and amygdala (4). BACE1, as 
the first protease to initiate Aβ production, has been shown to increase in 
activity and protein levels in the tissue and CSF of AD brains (3). Within 
astrocytes specifically, BACE1 is regulated post-translationaly in a feed-
forward mechanism in response to inflammatory cytokines (i.e. TNF-α and 
IFN-γ) and Aβ oligomers (3, 9). 
Previous studies using autopsied AD brain tissue have identified genetic 
material of viable Chlamydia pneumoniae (CPn), an obligate intracellular, 
gram-negative respiratory pathogen (2). Once intranasally acquired, CPn is 
thought to pass through the olfactory bulb and into the entorhinal and 
perirhinal cortices, hippocampus, and amygdala (5). This proposed route of 
CPn travel is also supported by the clinically apparent loss of smell (anosmia) 
notable in the earlier stages of the disease (1). In vitro studies describing the 
glial response to infection, however, are lacking. Therefore, this study will 
attempt to profile APP processing and the localization of BACE1 in human 
CCF-STTG1 astrocytes infected with CPn AR39. 
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